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ADSORB: A Prospective Randomised Study on the Efﬁcacy of Endovascular
Grafting vs. Best Medical Treatment in Uncomplicated Acute Dissection
of the Descending Aorta
R.J. Hinchliffe*, M.M. Thompson
St George’s Vascular Institute, London, United KingdomMany of the arterial lesions that vascular surgeons treat are on
the decline, and those that currently are may soon be offered more
effective drug therapy. In contrast, dissections of the aorta are
increasing and are likely to represent a signiﬁcant future workload
and challenge for vascular surgeons. Traditionally acute Stanford
type B dissections of the aorta were managed by a variety of
specialists, often cardiologists. Vascular surgeons only became
involved where peripheral ischaemia supervened.
Dake demonstrated the feasibility of placing endovascular stent-
grafts in to dissected aortas.1 This approach appeared to offer an
attractive alternative to traditional open surgical approaches for
complicated aortic dissection which carried high rates of compli-
cations.2 Consequently stent-grafts have been used increasingly in
this group of patients.3
Early efforts to reduce mortality from acute type B dissection
demonstrated that effective blood pressure control in the early
stages reduced mortality. Medical therapy did not necessarily
prevent long-term aortic related complications. The INSTEAD Trial
attempted to answer the question whether there was any beneﬁt
from placing a stent-graft in type B aortic dissection in the sub-
acute phase (2e52 weeks).4 There was no reduction in aortic
related mortality 2 years after the initial dissection but preliminary
data from INSTEAD suggests that stent-grafting might be protective
in the longer term (5 years).
The next question is whether there would be any additional
beneﬁt (or harm) from stenting patients within the ﬁrst 2 weeks of
their initial uncomplicated type B dissection? There remains scope
for improvement in the 10% in-hospital mortality when treated
with medical therapy.5 It is possible that stenting might reduce
mortality. However, concerns remain (due in part to a lack of data)
that stenting within the ﬁrst 2 weeks may be associated with
signiﬁcant risks even when the aortic dissection is uncomplicated.
It is for these reasons that we have been following the develop-
ment of the ADSORB trial keenly since its inception in 2002.
Recruitmenthasbeen slow, suggestinga lackof clinical equipoise and
the change of power calculation is regrettable but seems realistic ifDOI of original article: 10.1016/j.ejvs.2012.03.023.
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not have the power to demonstrate signiﬁcant differences in the
more robust clinical endpoints (aortic related or all-causemortality).
It is not clear whether the primary trial composite endpoint of
a variety of aortic related events (false lumen thrombosis, aortic
dilatation >5 mm, aortic rupture) at 1-year will be a clinically rele-
vant one for patients. In the INSTEAD Trial 20% of patients managed
non-operatively achieved false lumen thrombosis. It is quite possible
that this group of patients receiving early stent-grafting in the
ADSORBtrialmightnotderive anybeneﬁt at all (andmaybeharmed).
Signiﬁcant ADSORB trial design issues exist. The inclusion of
patients who are very young (lower limit of 18 years old) means
signiﬁcant numbers of patients with connective tissue disease
(previously diagnosed or otherwise) may be recruited. We know
this group appear to behave differently.6 Because the trial was
initiated some 10 years ago emerging evidence on the length of
coverage of aortic stent-graft and onmedical therapy have not been
incorporated and may skew outcomes.7,8 The triallists also need to
be clear on what they consider to be ‘complicated’. For example
does a DeBakey type IIIb dissection with one renal artery emerging
from the false lumen with only minor renal functional impairment
constitute a complicated or uncomplicated type B dissection?
The authors are to be congratulated on performing a rando-
mised trial in an acute setting. The ADSORB trial will be a useful
addition to the literature. But are the ﬁndings of the ADSORB trial
likely to change clinical practice? The results would only change
practice if there were signiﬁcant increases in the proportion of
patients who developed aortic remodelling or there was a signiﬁ-
cant reduction in the early mortality compared with best medical
therapy. The trouble is that we already know aortic remodelling
occurs in the overwhelming majority (90þ%) of patients who are
stented up to 3 months or longer after their acute dissection. And
the trial is not powered to detect a reduction in early mortality.
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